We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+22.99%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$569M
Cap. Flow
+$474M
Cap. Flow %
62.53%
Top 10 Hldgs %
80.56%
Holding
85
New
22
Increased
12
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$106M
2
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$22.5M
3
NVTA
Invitae Corporation
NVTA
+$11.7M
4
EXEL icon
Exelixis
EXEL
+$8.18M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.79M

Top Sells

Rank Stock Value
1
OSUR icon
OraSure Technologies
OSUR
+$7.61M
2
QDEL icon
QuidelOrtho
QDEL
+$6.75M
3
IMMU
Immunomedics Inc
IMMU
+$6.49M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.48M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.13M

Sector Composition

Rank Sector Weight
1 Healthcare 43.51%
2 Consumer Staples 0.62%
3 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$31.3B
$3.02M 0.4%
32,660
+2,328
+8% +$208K
ALXN
27
DELISTED
Alexion Pharmaceuticals
ALXN
$2.96M 0.39%
18,938
-11,139
-37% -$1.43M
ITMR
28
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$2.79M 0.37%
140,524
– –
ESTA icon
29
Establishment Labs
ESTA
$2.6B
$2.52M 0.33%
+66,921
New +$1.76M
NEO icon
30
NeoGenomics
NEO
$2.02B
$2.47M 0.33%
+45,951
New +$2.08M
RFL icon
31
Rafael Holdings
RFL
$104M
$2.44M 0.32%
106,203
– –
MRK icon
32
Merck
MRK
$318B
$2.32M 0.31%
29,769
+1,914
+7% +$146K
TPTX
33
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.32M 0.31%
+19,013
New +$2.08M
ABBV icon
34
AbbVie
ABBV
$429B
$2.3M 0.3%
+21,477
New +$2.06M
EIGR
35
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.28M 0.3%
6,191
-9,561
-61% -$2.74M
CMPS
36
Compass Pathways
CMPS
$1.83B
$2.04M 0.27%
42,743
-114,239
-73% -$4.87M
ONCR
37
DELISTED
Oncorus, Inc.
ONCR
$1.82M 0.24%
+56,422
New +$1.31M
PRVB
38
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$1.79M 0.24%
105,941
-33,477
-24% -$502K
MRTX
39
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.72M 0.23%
+7,838
New +$1.69M
OSH
40
DELISTED
Oak Street Health, Inc.
OSH
$1.69M 0.22%
27,612
-31,280
-53% -$1.64M
NVRO
41
DELISTED
NEVRO CORP.
NVRO
$1.66M 0.22%
9,589
-2,337
-20% -$378K
CRSP icon
42
CRISPR Therapeutics
CRSP
$5.09B
$1.66M 0.22%
10,825
+625
+6% +$73.9K
TRIL
43
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.53M 0.2%
103,819
-8,923
-8% -$129K
ADVM
44
DELISTED
Adverum Biotechnologies
ADVM
$1.47M 0.19%
13,599
-22,836
-63% -$2.83M
KDMN
45
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.4M 0.18%
336,442
+135,601
+68% +$535K
VRDN icon
46
Viridian Therapeutics
VRDN
$2.4B
$1.33M 0.18%
+81,185
New +$1.22M
PVLA
47
Palvella Therapeutics
PVLA
$2.29B
$1.25M 0.16%
6,250
– –
SRRK icon
48
Scholar Rock
SRRK
$6.08B
$1.19M 0.16%
+24,484
New +$889K
ZYME icon
49
Zymeworks
ZYME
$1.74B
$1.07M 0.14%
22,631
-66,602
-75% -$3.09M
CRDF icon
50
Cardiff Oncology
CRDF
$74.8M
$1.02M 0.14%
56,909
-224,910
-80% -$3.95M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Soleus Capital Management held 85 positions worth $758M, up 302% from $189M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Soleus Capital Management deployed $474M of net new capital in Q4 2020, opening 22 new positions and adding to 12 existing holdings. Its largest new stake was BioAtla: 63,587 shares worth $108M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Real Estate.

On the sell side, the largest reduction was Inhibrx, Inc. Common Stock, an estimated $5.13M trimmed.

  • Soleus Capital Management's largest Q4 2020 buy was BioAtla: 63,587 shares worth $108M.
  • Soleus Capital Management added most to LYRA THERAPEUTICS INC in Q4 2020, an estimated $3.89M increase.
  • Soleus Capital Management's biggest Q4 2020 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.13M.
  • Soleus Capital Management fully exited OraSure Technologies in Q4 2020, selling an estimated $7.61M.
  • Soleus Capital Management's ten largest holdings make up 81% of its $758M portfolio in Q4 2020.
  • Soleus Capital Management opened 22 new positions and closed 20 in Q4 2020.
  • Soleus Capital Management's portfolio value rose 302% quarter-over-quarter to $758M.

Based on Soleus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.